Lv51
1170 积分 2023-02-02 加入
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
9小时前
已完结
T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
4天前
已完结
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
1个月前
已完结
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma
1个月前
已完结
From G12C To Pan-RAS: The Expanding Therapeutic Landscape of KRAS-Mutant NSCLC
1个月前
已完结
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
2个月前
已完结
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2个月前
已完结
High-content CRISPR activation screens identify synthetically lethal RNA-based mechanisms to sensitize cancer cells to targeted T cell cytotoxicity
3个月前
已完结
Immunometabolic gatekeeping: How tissue metabolism conditions tumor immunity
3个月前
已关闭
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
3个月前
已完结
皖公网安备34019202002308
